The Federal Circuit’s refusal to reconsider its ruling forcing Teva to delist asthma-inhaler patents from the FDA’s Orange ...

Teva Pharmaceuticals filed a patent infringement lawsuit against Amneal Pharmaceuticals alleging that their generic version of ...

Late last year we reported on the United States Court of Appeals for the Federal Circuit decision holding that certain device patents should not ...

The FDA has approved the first generic versions of Johnson & Johnson's big-selling anticoagulant Xarelto, which brought in ...

Good afternoon, and welcome to the Evoke Pharma fourth quarter and full-year 2024 earnings conference call. (Operator Instructions) Please be advised that today's call is being recorded. I would now ...

The USFDA has established an office in India to oversee the number of Indian manufacturers qualified to supply generic ...

IPA also stated that while generics are priced lower than the corresponding brands, it is unfair and unacceptable to link quality with cost.

A much-anticipated meeting between President Donald Trump and representatives of the pharmaceutical industry took place ...

Asserting that quality standards are not region-dependent, the Indian Pharmaceutical Alliance (IPA) on Wednesday refuted the ...

Evoke Pharma Inc (EVOK) nearly doubles its annual revenue, reduces net loss, and outlines ambitious growth strategies for ...

Q4 2024 revenue increased 24.6% over Q3 2024; Full-year 2024 revenue grew 97.8% year-over-yearStrong growth in key commercial metrics, including ...

VOQUEZNA® (vonoprazan) generated $55.3 million in 2024 net revenues in its first full year of launch, driven by strong demand, including $29.7 ...